Go Deep
Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,413 | -0.9 | 1.18 | 0.10 | 409.50 |
| Oct 2026 | 21,464 | -0.9 | 1.16 | 0.10 | 400.68 |
| Oct 2026 | 21,451 | -0.9 | 1.16 | 0.10 | 402.63 |
| Oct 2026 | 21,586 | -0.9 | 1.11 | 0.10 | 381.70 |
| Oct 2026 | 21,548 | -0.9 | 1.12 | 0.10 | 387.80 |
| Oct 2026 | 21,496 | -0.9 | 1.15 | 0.10 | 395.38 |
| Oct 2026 | 21,599 | -0.9 | 1.10 | 0.10 | 379.27 |
| Oct 2026 | 21,573 | -0.9 | 1.11 | 0.10 | 382.28 |
Vanda Pharmaceuticals Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 50,529,000.0 | 51,718,000.0 | 57,216,000.0 | 56,258,000.0 |
| Net Profit | -62,513,000.0 | -48,567,000.0 | -141,187,000.0 | -22,586,000.0 |
| EPS | -1.0 | -0.8 | -2.4 | -0.4 |
Vanda Pharmaceuticals Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 216,105,000.0 | 198,772,000.0 | 192,640,000.0 | 254,382,000.0 |
| Net Profit | -220,474,000.0 | -18,900,000.0 | 2,509,000.0 | 6,275,000.0 |
| EPS | -3.7 | -0.3 | 0.0 | 0.1 |
Vanda Pharmaceuticals Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 488,948,000.0 | 656,204,000.0 | 648,440,000.0 | 634,247,000.0 | — |
| Total Liabilities | 161,762,000.0 | 117,658,000.0 | 103,530,000.0 | 107,049,000.0 | — |
| Total Equity | 327,186,000.0 | 538,546,000.0 | 544,910,000.0 | 527,198,000.0 | — |
Owes vs Owns
Vanda Pharmaceuticals Inc. owed $0.47 for every $1 it owned in Jun 2026, up from $0.17 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.47× | 0.33× | 0.18× | 0.16× | 0.17× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Vanda Pharmaceuticals Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 54.0%Receivables 11.2%Fixed assets (tangible) 2.8%Intangible assets 23.9%Other assets 7.8%
How it's funded — Dec 2025
Short-term debt 1.1%Long-term debt 1.4%Payables 1.0%Other liabilities 29.5%Shareholders' equity 66.9%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 263.8 | 374.6 | 388.3 | 466.9 |
| Receivables | 54.6 | 47.1 | 34.2 | 33.5 |
| Inventory | 1.9 | 1.7 | 1.4 | 1.2 |
| Fixed assets (tangible) | 13.5 | 12.7 | 9.1 | 11.0 |
| Intangible assets | 117.1 | 114.1 | 121.4 | 18.6 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 38.1 | 106.0 | 94.2 | 103.1 |
| Liabilities & equity | ||||
| Short-term debt | 5.6 | 4.3 | 2.4 | 2.3 |
| Long-term debt | 7.1 | 8.1 | 7.0 | 8.8 |
| Payables | 4.9 | 3.5 | 7.1 | 12.7 |
| Other liabilities | 144.2 | 101.8 | 87.0 | 83.2 |
| Shareholders' equity | 327.2 | 538.5 | 544.9 | 527.2 |
| Net tangible assets | 210.1 | 424.4 | 423.5 | 508.6 |
Vanda Pharmaceuticals Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -109,442,000.0 | -15,757,000.0 | 12,801,000.0 | 31,984,000.0 | — |
| Investing Activities | 94,860,000.0 | -17,430,000.0 | -12,056,000.0 | 49,925,000.0 | — |
| Financing Activities | -2,906,000.0 | -155,000.0 | 0.0 | 734,000.0 | — |